Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 9/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | YAP1 | P46937 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13131881 | 1.00 | REN (0.53) | RENNR1H4JAK2JAK1YAP1 | |
| SCHEMBL13169068 | 0.91 | REN (0.56) | RENNR1H4PDE4B | |
| SCHEMBL2810181 | 0.91 | REN (0.64) | RENNR1H4PDE4B | |
| SCHEMBL13131884 | 0.91 | REN (0.64) | RENNR1H4PDE4B | |
| SCHEMBL2805889 | 0.88 | REN (0.45) | RENNR1H4JAK2JAK1YAP1 | |
| SCHEMBL18508872 | 0.87 | REN (0.58) | REN | |
| SCHEMBL16471579 | 0.86 | REN (0.68) | REN | |
| SCHEMBL15435856 | 0.86 | REN (0.68) | REN | |
| SCHEMBL13131880 | 0.85 | REN (0.66) | RENNR1H4JAK2JAK1 | |
| SCHEMBL13132467 | 0.85 | REN (0.48) | RENNR1H4JAK2JAK1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168952-B1 | MORPHOLINE DERIVATIVES AS RENIN INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| EP-2168952-A1 | MORPHOLINE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | REN, AGTR1, AGTR2 | REN 1/4885NR1H4 574/4885JAK2 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.